NovoCure (NVCR) Stock Faces Ongoing Losses As Q2 2026 EPS Narrows To $0.13 Loss

Fresh out of its Q2 2026 report, NovoCure (NVCR) posted total revenue of US$183.6 million and a basic EPS loss of US$0.13, with trailing twelve month revenue at US$699.2 million and a full year EPS loss of US$1.31. The company has seen quarterly revenue move from US$158.8 million in Q2 2025 to US$183.6 million in Q2 2026. Basic EPS losses across recent quarters have ranged from US$0.31 to US$0.62, underlining an earnings profile that remains in the red even as top line figures scale higher. For investors, the focus this quarter is on how quickly margins can recover from these ongoing losses and how that balances against the growth-oriented reward case already reflected in expectations.

See our full analysis for NovoCure.

With the latest numbers on the table, the next step is to see how this earnings print lines up with the prevailing narratives around NovoCure's growth potential, profitability path, and risk profile.

See what the community is saying about NovoCure

Margins Still Negative With US$148.6 Million LTM Loss

• Over the last twelve months, NovoCure reported total revenue of US$699.2 million and a net loss of US$148.6 million, so the business is still spending more than it brings in on a trailing basis.
• Bears point out that losses have widened at about 21.9% per year over the past five years, and the latest trailing loss of US$148.6 million fits that concern. However, the current Q2 2026 loss of US$15.7 million compares with much larger recent quarterly losses, which challenges the idea that operating performance is only moving in the wrong direction.
  • Critics highlight that Q1 2026 saw a loss of US$71.1 million, so the last two quarters together still show a heavy hit to net income even with Q2 looking lighter.
  • At the same time, trailing twelve month revenue has moved from US$630.2 million in Q2 2025 to US$699.2 million in Q2 2026, so the bearish worry is that expanding revenue has not yet translated into positive earnings.

For readers trying to work out how recent clinical and commercial progress might offset this loss profile, it helps to see exactly how the more optimistic investors are framing their case on NovoCure's long term earnings power and expansion plans. 🐂 NovoCure Bull Case

Revenue Growth Story Versus 58.9% Earnings Forecast

• The analysis points to forecast revenue growth of about 16.3% per year and forecast earnings growth of about 58.9% per year, while the latest trailing twelve month figures still show a loss of US$148.6 million on US$699.2 million of revenue.
• Supporters of the bullish view argue that strong clinical adoption and geographic expansion could justify those higher growth forecasts, and the recent move from US$158.8 million in revenue in Q2 2025 to US$183.6 million in Q2 2026, alongside an EPS loss narrowing from US$0.36 to US$0.13 over the same quarters, is used as evidence that revenue scale and operating improvements are starting to line up with that thesis.
  • Consensus narrative also references multiple late stage trials and new indications, and the trailing twelve month revenue lift from US$630.2 million in Q2 2025 to US$699.2 million in Q2 2026 is one concrete sign that the addressable market is beginning to show up in the reported numbers.
  • What stands out, though, is that even with those trends, the trailing loss of US$148.6 million shows the gap that still has to close for the 58.9% annual earnings growth expectation to be reflected in actual profitability.

P/S Of 2.9x And Volatile Share Price

• NovoCure trades on a P/S of 2.9x, which the analysis notes is below the peer average of 7.3x and roughly in line with the US Medical Equipment industry at 2.8x, while the current share price of US$17.65 is compared with an analyst target of US$27.14 and a DCF fair value of US$229.58 in the data set.
• Bears argue that share price volatility and significant insider selling over the past three months sit awkwardly with the large gap between US$17.65 and the US$229.58 DCF fair value, and they point to the five year trend of losses widening at 21.9% per year and the latest twelve month loss of US$148.6 million as reasons why the market might be hesitant to price NovoCure closer to growth focused models.
  • What is clear from the figures is that investors are being asked to weigh a P/S that looks lower than peers against a business that remains unprofitable on both a quarterly and trailing basis.
  • For a cautious investor, the combination of insider selling, recent volatility and a long history of losses can make the discount to the US$27.14 analyst target and the much higher US$229.58 DCF fair value look more like a risk check than a simple bargain signal.

If you are trying to understand why some investors remain skeptical even with a lower P/S multiple, it is worth reading the detailed cautious case that sets out how regulatory, reimbursement and competitive pressures could keep NovoCure's profitability under strain. 🐻 NovoCure Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for NovoCure on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views on NovoCure across growth, valuation and risk, this is a moment to move quickly and test the numbers against your own expectations. To weigh the trade off between the concerns and the potential rewards in one place, review the 2 key rewards and 2 important warning signs

See What Else Is Out There Beyond NovoCure

NovoCure is still working through sizeable losses and volatile sentiment, with a history of widening earnings pressures that leaves some investors uncomfortable with the risk profile.

If that level of uncertainty feels a bit heavy, you can quickly compare this situation with companies that score better on financial resilience by checking the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com